Efficacy and safety of ¹⁷⁷Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.

ABSTRACT:

Purpose

NETTER-R aimed to determine the efficacy, safety and tolerability of ¹⁷⁷Lu-DOTATATE in patients with progressive, advanced pancreatic neuroendocrine tumours (panNETs) using retrospective real-world data from multiple sites.

Methods

This international study retrospectively included patients with panNETs treated with ¹⁷⁷Lu-DOTATATE. The primary endpoint was progression-free survival (PFS) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Secondary endpoints included overall survival (OS), safety and tumour response.

Results

In total, 110 patients with panNETs were studied; 65.5% received a cumulative dose of ¹⁷⁷Lu-DOTATATE 29.6 GBq ± 10% (median: 7.4 GBq). In 62 patients with available RECIST v1.1 tumour

SUBMITTER: Clement D 

PROVIDER: S-EPMC9308585 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature